Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review

The selective estrogen receptor modulator tamoxifen is used in the treatment of early and advanced breast cancer and in selected cases for breast cancer prevention in high-risk subjects. The cytochrome P450 enzyme system and flavin-containing monooxygenase are responsible for the extensive metabolism of tamoxifen into several phase I metabolites that vary in toxicity and potencies towards estrogen receptor (ER) alpha and ER beta.An extensive overview of publications on the determination of tamoxifen and its phase I metabolites in biological samples is presented. In these publications techniques were used such as capillary electrophoresis, liquid, gas and thin layer chromatography coupled with various detection techniques (mass spectrometry, ultraviolet or fluorescence detection, liquid scintillation counting and nuclear magnetic resonance spectroscopy). A trend is seen towards the use of liquid chromatography coupled to mass spectrometry (LC-MS). State-of-the-art LC-MS equipment allowed for identification of unknown metabolites and quantification of known metabolites reaching lower limit of quantification levels in the sub pg mL⁻¹ range. Although tamoxifen is also metabolized into phase II metabolites, the number of publications reporting on phase II metabolism of tamoxifen is scarce. Therefore the focus of this review is on phase I metabolites of tamoxifen.We conclude that in the past decades tamoxifen metabolism has been studied extensively and numerous metabolites have been identified. Assays have been developed for both the identification and quantification of tamoxifen and its metabolites in an array of biological samples. This review can be used as a resource for method transfer and development of analytical methods used to support pharmacokinetic and pharmacodynamic studies of tamoxifen and its phase I metabolites.     

Prospective study to assess the clinical efficacy of bone scintigraphy--some analyses of clinical data

The value of preoperative bone scans in patients with primary breast and prostate cancer was evaluated prospectively. Of 414 patients with breast cancer, clinical stage I is 14, II is 219, IIIA is 59, IIIB is 39 and IV is 14. Of 88 patients with prostate cancer, clinical stage I is 14, II is 15, III is 18 and IV is 41. 11 percent of patients with breast cancer and 54 percent of patients with prostate cancer had bone metastases. Clavicle, ribs, thoracic spine, lumbar spine and pelvis metastasized most frequently. The incidences of bone metastases were 18.4% with Scirrhous carcinoma, 15.4% with Medullary tubular carcinoma and 3.8% with Papillotubular carcinoma. The methodology and results of ROC analysis were described in our other papers. Some results of data analysis were described in this paper.     

Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection

Sensitive methods were developed for the analysis of dextromethorphan (I) and two metabolites, (+)-17-methyl-morphinan-3-ol (II) and (+)-morphinan-3-ol (III), in plasma as well as dextromethorphan and three metabolites II, III and (+)-3-methoxymorphinan (IV) in urine using high-performance liquid chromatography followed by detection with a fluorometer. Dextromethorphan and its metabolites were extracted from plasma and urine and separated in the reversed-phase mode. The practical lower limits of determination for I, II, and III in plasma were 0.5, 5, and 5 ng/ml, respectively; for I, II, III, and IV in urine, the limits were 20 ng/ml, 0.6 microgram/ml, 0.5 microgram/ml, and 15 ng/ml, respectively. The linearity of the calibration graphs was excellent (r varied from 0.9994 to 0.9999) over concentration ranges of two orders of magnitude.     

Developmental studies of electrical properties in cultured rat brain neurons

The rat brain neurons isolated from 15--17-day embryos were grown in dissociated cell culture and maintained in vitro for 3 weeks. The developmental process of the neurons was observed from the early stage of development in terms of passive and active electrical parameters and their changes induced by perfusion of ionic channel blockers. The neurons' development could be morphologically divided into stages I (from seedling to 6 days), II (7-11 days), III (12-20 days) and IV (21-22 days). The relative values of resting membrane potentials (RMP) for stages I, II, III and IV were 1, 3.46, 4.07 and 6.54, respectively; the corresponding values of input resistance (Rin) were 1, 1.48, 2.53 and 4.56, respectively. The current-voltage relationship in stages II and III was exponential in the direction of depolarization and the Rin's change with time was nearly linear. Spontaneous activities increased with prolongation of culture and the amplitude of evoked action potentials reached the maximum during stages III and IV. The RMP and Rin were markedly decreased by perfusion of TEA while no change was seen in TTX perfusion group. The results indicate that potassium ionic channels develop slower in stages II and IV, faster in stages I and III and mature by the end of stage IV.     

Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers

HLA expression is altered in a large variety of human cancers. We performed immunohistochemical staining on tissues from normal, preinvasive, invasive and metastatic cervical cancer tissues using anti-HLA class I or class II antibody. In tissues from normal squamous epithelium, carcinoma in situ (CIS) and microinvasive carcinoma (MIC), the expressions of HLA-B, C heavy chains and class II heavy chain were significantly decreased as disease progressed. When the expression patterns were compared between primary and metastatic squamous cell carcinoma (SCC) lesions, statistically significant down-regulation of HLA class I and class II antigen in metastatic lesions was observed. The rates of HLA-B, C heavy chains and class II heavy chain expressions were all significantly down-regulated compared to the down-regulation rate of class I beta2-microglobulin (beta2m) in invasive squamous lesions, and the expressions of class II heavy chain in metastatic lesions was decreased further than that in primary lesions. Unlike SCC, the degree of HLA class I and class II loss was not evident as disease progressed in early stage of adenocarcinoma. In invasive adenocarcinoma lesions, only the expression of HLA-B, C heavy chains was decreased and no differences were seen in HLA-B, C heavy chain expression patterns between primary and metastatic lesions. These results suggest that alterations of HLA class I and II expressions seem to occur at a particular step in cervical cancer development and depend on tissue types: when the tumor becomes invasive and starts to metastasize.     

The identification of three human metabolites of a peptide-doxorubicin conjugate using HPLC-MS-MS in positive and negative ionization modes

A peptide-doxorubicin conjugate (I) is a drug candidate that has been evaluated for the treatment of prostate cancer. During the high-performance liquid chromatographic (HPLC)-fluorescence analysis of clinical samples for compound I and its two known metabolites [doxorubicin (II) and leucine-doxorubicin (III)], additional metabolites are observed in postdose human plasma extracts. Using neutral loss, precursor, and product ion tandem mass spectrometric (MS-MS) experiments, two of these metabolites are identified as doxorubicinol (IV) and leucine-doxorubicinol (V), the active 13-hydroxy metabolites of doxorubicin and leucine-doxorubicin, respectively. A third metabolite, 7-deoxydoxorubicinol aglycone (VI), is detected using single-ion monitoring at m/z 399 in the negative ionization mode. The product ion mass spectrum of this metabolite contains a major fragment at m/z 351, resulting from the loss of water and formaldehyde from the pseudomolecular ion. An HPLC-MS-MS method for simultaneous analysis of II, III, IV, V, and VI is developed utilizing gradient HPLC with a combination of positive/negative ionization MS in the multiple reaction monitoring mode and monitoring the appropriate MS-MS transitions. Using this methodology, rat, dog, and human plasma metabolite profiles are compared and found to be qualitatively similar. Simultaneous fluorescence and MS detection experiments confirm that the peaks observed in the HPLC-fluorescence chromatograms of plasma extracts correspond to each of the five metabolites (II-VI).     

In silico study of cancer stage-specific DNA methylation pattern in White breast cancer patients based on TCGA dataset

BackgroundBreast cancer is one of the most common types of cancer among women. As current breast cancer treatments are still ineffective, we assess the methylation pattern of White breast cancer patients across cancer stage based on The Cancer Genome Atlas (TCGA) dataset. Significant hypermethylation and hypomethylation can regulate the gene expression, thus becoming potential biomarkers in breast cancer tumorigenesis.MethodsDNA methylation data was downloaded using TCGA Assembler 2 based on race-specific metadata of TCGA - Breast Invasive Carcinoma (TCGA-BRCA) project from Genomic Data Commons (GDC) Data Portal. After the data was divided into each cancer stage, duplicated data of each patient was removed using OMICSBind, while differentially-expressed probes were identified using edgeR. The resulting probes were validated based on correlation and regression analysis with the gene expression, ANOVA between cancer stages, ROC curve per stage, as well as databases.ResultsBased on the White dataset, we found 66 significant hypermethylated genes with logFC > 1.8 between Stage I-III. From this number, three epigenetic-regulated, stage-specific genes are proposed to be the detection biomarkers of breast cancer due to significant aberrant gene expression and/or low mutation ratio among breast cancer patients: ABCC9 (Stage III), SHISA3 (Stage II), and POU4F1 (Stage I-II).ConclusionsOur study shows that ABCC9, SHISA3, and POU4F1 are potential stage-specific detection biomarkers of breast cancer for White individuals, whereas their roles in other races need to be studied further.     

Elevated levels of hydroxylated phosphocholine lipids in the blood serum of breast cancer patients

The difference in serum phospholipid content between stage‐IV breast cancer patients and disease‐free individuals was studied by employing a combination of chemometric statistical analysis tools and mass spectrometry. Chloroform‐extracted serum samples were profiled for their lipid class composition and structure using precursor ion, neutral loss, and product ion tandem mass spectrometric (MS/MS) scanning experiments. Changes in the relative abundance of phospholipids in serum as a consequence of cancer progression, measured through electrospray ionization (ESI) mass spectrometry of flow‐injected serum samples collected from 25 disease‐free individuals and 50 patients diagnosed with stage‐IV breast cancer, were statistically evaluated using principal component analysis (PCA), analysis of variance (ANOVA) and receiver operating characteristic (ROC) analysis. Lipids whose abundance changed significantly as a consequence of cancer progression were structurally characterized using product ion spectra, and independently quantified using precursor ion scan experiments against an internal standard of known concentration. Phosphocholine lipids that displayed a statistically significant change as a consequence of cancer progression were found to contain an oxidized fatty acid moiety as determined by MS³ experiments. Copyright © 2009 John Wiley & Sons, Ltd.     

Differential scanning calorimetry (DSC) of blood serum in chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a major global health challenge with a gloom perspective of being one of the big three cause of death by 2020. No reliable/reproducible biomarker has been identified so far to match the clinically-based staging system (GOLD). Blood samples of 30 subjects divided into 6 groups (no-COPD/-smoker, no-COPD/non-smoker, COPD I, COPD II, COPD III, COPD IV) with 5 patients in each were tested by differential scanning calorimetry. There is a clear 15.4 % difference between the heat flow maxima measured when no-COPD subjects were compared in accordance to their smoking/non-smoking status. Odds ratio of different heat flow in actively smoking COPD patients in stage IV and stage I was 1.61. A reverse tendency is detected in the relevant non-smoking COPD groups. The differences are inconsistent in intermediate stages (COPD II and III). DSC seems to be an applicable and objective method for monitoring nicotine abuse. There is a chance to detect specific typology of thermokinetic patterns in the two extremes of COPD (I vs. IV). Further studies with increased sample size are needed to allow calculations on specificity/sensitivity/positive and negative predictive value of enthalpies and heat flow maximums. The first clinically relevant blood-based COPD marker on the intravascular side of the alveo-capillary screen is demonstrated by our pilot study.     

Urocanic Acid Concentration and Photoisomerization in Caucasian Skin Phototypes

Abstract— To investigate the relationship between erythemal sensitivity of the skin to U V radiation and epidermal urocanic acid (UCA) concentration, 45 healthy volunteers of anamnestic skin phototypes (ASP) I-IV were studied. In 16 of the subjects, we analyzed UCA photoisomerization after graded UVB exposures. The median and mean total UCA concentration in unirradiated skin was 22.4 and 35.3 nmol/cm², and no statistically significant difference in total UCA concentrations was detectable either between ASP I through II and III through IV or between the phototested skin type (PSP) groups 1 through 2 and 3 through 4. The relative amount of the cis -isomer varied between 3 and 35%, with median and mean values of 7 and 12%, respectively. No statistically significant difference in absolute or relative cis -UCA concentrations was detectable between ASP I through II and III through IV, but a significantly lower absolute ( P < 0.009) and relative ( P < 0.002) cis -UCA concentration in unirradiated skin was recorded in PSP groups 1 through 2, compared to types 3 through 4. In all tested subjects, an erythemally weighted dose of 1 mj/cm²sufficed to cause trans - to cis -UCA isomerization. When comparing photosensitive (skin phototype I) and phototolerant (phototypes III and IV) individuals, who were irradiated with a reference 5 mJ/cm²UV dose or with fractions of 0.1-1.0 of their individual minimal erythema dose values, no skin phototype-dependent difference in ability to photoisomerize was discernible.     

Chloroform extraction of ethyl xanthate complexes from sulphuric acid media

The chloroform extraction of 30 elements (Fe, Co, Ni, Zn, Cd, Ge, Sn, V, As, Sb, Bi, Cu, Ag, Au, Mn, Re, Ga, In, Tl, Se, Te, Cr, Mo, U, Pt, Pd, Rh, Ir, Ru and Ce) from 0.1-8M sulphuric acid in the presence of potassium ethyl xanthate has been studied. Pd(II), Bi, As(III), Sb(III), Se(IV) and Te(IV) are completely extracted and Au(III) is largely extracted over the range of acid concentration investigated. Fe(II), Tl(I), Rh(III) and Cr(VI) are only slightly extracted and Se(VI), Te(VI), Ru(III), Cr(III), Mn(II), Zn, Ce(IV), Ir(IV) and Ge(IV) are not extracted at all. Depending on the acid concentration, the remaining elements are all partly extracted. Results are compared with those obtained in an earlier study of the extraction of xanthate complexes from hydrochloric acid media. The processes involved in the formation of some xanthate complexes and potential analytical separations are discussed.     

Analytical applications of a liquid anion-exchanger for the separation of uranium(IV) in malonate solution

Uranium was quantitatively extracted with 4% Amberlite LA-1 in xylene at pH 2.5-4.0 from 0.001 M malonic acid. It was stripped from the organic phase with 0.01 M sodium hydroxide and determined spectrophotometrically at 530 nm as its complex with 4-(2-pyridylazo) resorcinol. Of various liquid anion-exchangers tested, Amberlite LA-1 was found to be best. Uranium was separated from alkali and alkaline earth metal ions, thallium(I), iron(II), silver, arsenic(III) and tin(IV) by selective extraction, and from zinc, cadmium, nickel, copper(II), cobalt(II), chromium(III), aluminium, iron(III), lead, bismuth, antimony(III) and yttrium by selective stripping. The separation from scandium, zirconium, thorium and vanadium(V) was done by exploiting differences in the stability of chloro-complexes.     

Lactate and pyruvate levels correlation with lactate dehydrogenase gene expression and glucose consumption in Tamoxifen-resistant MCF-7 cells using capillary electrophoresis with contactless conductivity detection (CE-C4D)

Breast cancer is the second leading cause of cancer death in women after lung cancer. The first-line treatment of metastatic breast cancer in premenopausal women relies on tamoxifen. The development of tamoxifen resistance is not fully understood. In this study, capillary electrophoresis with capacitively coupled contactless conductivity detector was developed to monitor the changes in lactate and pyruvate levels in supernatant media of three models of developed MCF-7 tamoxifen-resistant cells and correlate these metabolites changes with lactate dehydrogenase genes expression and glucose consumption. The electrophoretic separation was achieved under reversed electroosmotic flow conditions. The linear ranges were 0.15–5 and 0.01–1 mM with a correlation coefficient of 0.9966 and 0.9971 and the limits of detection were 0.01 and 0.02 μM for lactate and pyruvate, respectively. Inter- and intrarun accuracy were in the range of 96.88–105.94% with precision (CV, %) of ≤7.35%. The method was completely validated and the results were in agreement with those obtained using the lactate and glucose assay kits. The results revealed a significant increase in both lactate and pyruvate production in the three tamoxifen-resistant MCF-7 cells models compared to control cells. This increase was correlated with the increase of lactate dehydrogenase genes expression and the increase of glucose consumption.     

Identification of tamoxifen and metabolites in human male urine by GC/MS

Tamoxifen is an antiestrogenic drug which is used in the treatment of breast cancer and nonmalignant breast disorders. It also has a stimulating effect on the secretion of hypofisar gonadotropic hormones and is generally used in the treatment of infertility. In males, tamoxifen causes an increase of endogenous production of androgenic steroids, and therefore is used by athletes. A method for identification of tamoxifen and metabolites in urine, using the gas chromatography and mass spectrometry system (GC/MS) is described. This study also reports the extraction methodology of tamoxifen and metabolites in urine samples of healthy male volunteers and the GC/MS conditions used to identify tamoxifen and its metabolites.     

Analysis of tamoxifen and its metabolites in synthetic gastric fluid digests and urine samples using high-performance liquid chromatography with electrospray mass spectrometry

We report on the transformation of tamoxifen at 37 degrees C in synthetic gastric fluid as studied by high-performance liquid chromatography with triple quadrupole mass spectrometry. The major transformation products detected were (E)-isomer of tamoxifen, metabolite D, and several unidentified components having m/z 404. Addition of pepsin to the gastric fluid inhibited formation of all of these products. We analyzed several urine samples from breast cancer patients undergoing tamoxifen treatment. Metabolite D was identified in the urine samples and in the gastric fluid digest at a retention time of 22.0 min eluting from a reversed-phase HPLC column. Although several metabolites were found in all the urine samples of patients, some metabolites were detected in one sample but not others, suggesting tamoxifen metabolism varies in patients.     

Utility of NBD-Cl for the spectrophotometric determination of some skeletal muscle relaxant and antihistaminic drugs

A simple, accurate, precise and sensitive colorimetric method for the determination of some skeletal muscle relaxant drugs, namely orphenadrine citrate (I), baclofen (II), antihistaminic drugs as acrivastine (III) and fexofenadine hydrochloride (IV) is described. This method is based on the formation of charge transfer complex with 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) in non-aqueous medium. The orange color products were measured at 472, 465, 475 and 469 nm for drugs I, II, III and IV, respectively. The optimization of various experimental conditions was described. Beer's Law was obeyed in the range (2.5-17.5), (5-70), (2.5-25) and (10-50)microg/ml for drugs I, II, III and IV, respectively. The molar absorptivity (epsilon), sandell sensitivity, detection((LOD)) and quantitation limits((LOQ)) are calculated. The procedure was favorably applied for determination of certain pharmaceutical dosage forms containing the studied drugs. The obtained results were compared with the official and reported methods. There were no significant differences between proposed, reported and the official methods.     

the extraction of some metallic bromides from aqueous solutions with methyl ethyl ketone and methyl iso-butyl ketone

The extraction of the following metals from aqueous solutions containing excess bromide with methyl ethyl ketone (MEK), and methyl isobutyl ketone MIBK has been investigated:—Cu(I), Cu(II), Zn(II), Ni(II), Co(II), Fe(II), Fe(III), Al(III), Mn(II), Sn(II) and Sn(IV). The use of MEK was found to be strictly limited by its solubility in acidic aqueous solutions. Determinations of the formulae of the extracted compounds were attempted in two cases but were found to be not wholly satisfactory and were discontinued. An interesting reaction between the cupric bromide complex and the solvents was noticed. Separations of Fe(IIl) from Mn(II), Fe(III) from Al(III), Fe(III) from Co(Il) and Fe(III) from Ni(II) could be achieved under suitable conditions.     

Solvent extraction separation of tin (IV) with 2-ethylhexyl phosphonic acid mono-2-ethylhexyl ester (PC-88A)

Solvent extraction of tin(IV) from hydrochloric acid media was carried out with 2-ethylhexyl phosphonic acid mono-2-ethylhexyl ester (PC-88A) in toluene. Tin(IV) was quantitatively extracted with 2.5x10(-2) M PC-88A in toluene from 0.1-0.3 M HCl when equilibrated for 5 min. Tin(IV) from the organic phase was stripped with 4 M HCl and determined spectrophotometrically by both the morin and pyrocatechol violet method. The nature of the extracted species was determined from the log-log plots. Various other diluents such as xylene, hexane and cyclohexane also gave quantitative extraction of tin. The metal loading capacity of the reagent was found to be 0-15 ppm of tin(IV). The extraction of tin(IV) was carried out in the presence of various ions to ascertain the tolerance limit of individual ions. Tin(IV) was successfully separated from commonly associated metal ions such as antimony(III), bismuth(III), lead(II), thallium(I), copper(II), nickel(II), etc. The method was extended for determination of tin in real samples.     

Extraktionsmethode zur Trennung kleiner Tellurmengen von Begleitelementen

Zusammenfassung Zur Trennung von Tellur aus Lösungen mit komplizierter Zusammensetzung wurde eine kombinierte Extraktionsmethode entwickelt. Die Extraktion von Eisen(III), Arsen(V), Antimon(V), Gold(III), Thallium(III), Wismut(III), Zinn(IV) und Selen(IV) erfolgt mit Diisopropyläther aus 8 M Salzsäure, wobei das gesamte Te(IV) in der wäßrigen Phase verbleibt. Diese wird dann mit Methylisobutylketon aus 4 M Salzsäure extrahiert, während in der wäßrigen Phase Kupfer(II), Aluminium(III), Silber(I), Nickel (II), Kobalt(II), Zink(II), Cadmium(II) und Blei(II) verbleiben. Die vollständige Abtrennung der Begleitelemente des Tellurs erfolgt durch zusätzliche Extraktion ihrer Kupferronate mit Methylisobutylketon bei pH 3–5. Das vorgeschlagene Extraktionsverfahren kann mit jeder bekannten Methode zur Bestimmung geringer Tellurmengen kombiniert werden.

---

Extraction method for the separation of small quantities of tellurium from accompanying elements

A new combined solvent extraction method is proposed for the separation of tellurium from solutions of complex composition. Iron(III), arsenic(V), antimony(V), gold(III), thallium(III)J bismuth(III), tin(IV) and selenium(IV) are extracted with diisopropyl ether from 8 M hydrochloric acid. Under these conditions tellurium(IV) is quantitatively retained in the aqueous phase. Subsequently tellurium(IV) is extracted from 4 M hydrochloric acid with methylisobutyl ketone, so that copper(II), aluminium(III), silver(I), nickel(II), cobalt(II), zink(II), cadmium(II) and lead(II) remain in. the aqueous phase. The complete separation of the accompanying elements is realized by an additional extraction of their cupferronates with methylisobutyl ketone at pH 3–5. The separation described can be combined with any known method for the determination of small amounts of tellurium(IV).